Pierre TONNERRE

Dr. Pierre TONNERRE

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016 in Science
Verified
Journal Article
Open access
PDF file
DSDebattama R. Sen
Debattama R. Sen
JKJames Kaminski
James Kaminski
RBR. Anthony Barnitz
R. Anthony Barnitz
MKMakoto Kurachi
Makoto Kurachi
UGUlrike Gerdemann
Ulrike Gerdemann
WHW. Nicholas Haining
W. Nicholas Haining
Exhausted T cells in cancer and chronic viral infection express distinctive patterns of genes, including sustained expression of programmed cell death protein 1 (PD-1). However, the regulation of gene expression in exhausted T cells is poorly understood. Here, we define the accessible chromatin landscape in exhausted CD8+ T cells and show that it is distinct from functional memory CD8+ T cells. Exhausted CD8+ T cells in humans and a mouse model of chronic viral infection acquire a state-specific epigenetic landscape organized into functional modules of enhancers. Genome editing shows that PD-1 expression is regulated in part by an exhaustion-specific enhancer that contains essential RAR, T-bet, and Sox3 motifs. Functional enhancer maps may offer targets for genome editing that alter gene expression preferentially in exhausted CD8+ T cells.

26 July 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
KYKathleen B. Yates
Kathleen B. Yates
PTPierre TONNERRE
Pierre TONNERRE
GMGenevieve E. Martin
Genevieve E. Martin
UGUlrike Gerdemann
Ulrike Gerdemann
RARose Al Abosy
Rose Al Abosy
DSDebattama R. Sen
Debattama R. Sen

22 December 2018 in Gut
Verified
Journal Article
Closed access
PDF file
RHRuben C Hoogeveen
Ruben C Hoogeveen
MRMaxwell P Robidoux
Maxwell P Robidoux
TSTatjana Schwarz
Tatjana Schwarz
LHLaura Heydmann
Laura Heydmann
JCJames A Cheney
James A Cheney
GLGeorg M. Lauer
Georg M. Lauer
Objective Chronic HBV infection affects more than 250 million people worldwide and remains a global healthcare problem in part because we lack curative treatment. Sustained viral control requires HBV-specific T cells, but these become functionally impaired in chronic infection. Clinical evidence indicates that functional cure of HBV infection by the host immune response is feasible. Developing T cell-based therapies able to achieve functional cure will require identification of the requirements for a successful T cell response against HBV and the relative contribution of individual T cell specificities to HBV control. Design The phenotype and function of HBV-specific T cells were studied directly ex vivo using fluorochrome-labelled multimers. We studied multiple HBV-specific T cell specificities targeting different HBV proteins in individuals with either an acute self-limiting or chronic HBV infection. Results We detected strong T cell responses targeting multiple HBV viral proteins in acute self-limiting and low-frequency core and polymerase-specific T cells in chronic infection. Expression of the T cell inhibitory receptor PD-1, as well as T cell differentiation, T cell function and T cell regulation differed by stages and outcomes of infection. In addition, these features differed significantly between T cells targeting different HBV specificities. Conclusion HBV-specific T cells with different target specificities are characterised by distinct phenotypical and functional profiles. These results have direct implications for the design of immunological studies in HBV infection, and are potentially relevant for informing immunotherapeutic approaches to induce functional cure.

26 July 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
PTPierre TONNERRE
Pierre TONNERRE
DWDavid Wolski
David Wolski
SSSonu Subudhi
Sonu Subudhi
JAJihad Aljabban
Jihad Aljabban
RHRuben C. Hoogeveen
Ruben C. Hoogeveen
GLGeorg M. Lauer
Georg M. Lauer

31 March 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
SMStuti Mehta
Stuti Mehta
DCD. Alexander Cronkite
D. Alexander Cronkite
MBMegha Basavappa
Megha Basavappa
Tahnee SaundersTahnee Saunders
Tahnee Saunders
FAFatemeh Adiliaghdam
Fatemeh Adiliaghdam
KJKate L. Jeffrey
Kate L. Jeffrey
Epigenetic “readers” that recognize defined posttranslational modifications on histones have become desirable therapeutic targets for cancer and inflammation. SP140 is one such bromodomain- and plant homeodomain (PHD)–containing reader with immune-restricted expression, and single-nucleotide polymorphisms (SNPs) within SP140 associate with Crohn’s disease (CD). However, the function of SP140 and the consequences of disease-associated SP140 SNPs have remained unclear. We show that SP140 is critical for transcriptional programs that uphold the macrophage state. SP140 preferentially occupies promoters of silenced, lineage-inappropriate genes bearing the histone modification H3K27me3, such as the HOXA cluster in human macrophages, and ensures their repression. Depletion of SP140 in mouse or human macrophages resulted in severely compromised microbe-induced activation. We reveal that peripheral blood mononuclear cells (PBMCs) or B cells from individuals carrying CD-associated SNPs within SP140 have defective SP140 messenger RNA splicing and diminished SP140 protein levels. Moreover, CD patients carrying SP140 SNPs displayed suppressed innate immune gene signatures in a mixed population of PBMCs that stratified them from other CD patients. Hematopoietic-specific knockdown of Sp140 in mice resulted in exacerbated dextran sulfate sodium (DSS)–induced colitis, and low SP140 levels in human CD intestinal biopsies correlated with relatively lower intestinal innate cytokine levels and improved response to anti–tumor necrosis factor (TNF) therapy. Thus, the epigenetic reader SP140 is a key regulator of macrophage transcriptional programs for cellular state, and a loss of SP140 due to genetic variation contributes to a molecularly defined subset of CD characterized by ineffective innate immunity, normally critical for intestinal homeostasis.

1 October 2017 in Immunity
Verified
Journal Article
Closed access
DWDavid Wolski
David Wolski
PFPeter K. Foote
Peter K. Foote
DCDiana Y. Chen
Diana Y. Chen
LLLia L. Lewis-Ximenez
Lia L. Lewis-Ximenez
CFCatherine Fauvelle
Catherine Fauvelle
GLGeorg M. Lauer
Georg M. Lauer